嗜酸性粒细胞是目前对严重的、无法控制的、伴有鼻息肉的慢性鼻窦炎进行生物治疗的主要 2 型标志物。

IF 4.8 2区医学 Q1 OTORHINOLARYNGOLOGY Rhinology Pub Date : 2024-06-01 DOI:10.4193/Rhin23.081

R van der Lans, J J Otten, G F J P M Adriaensen, L B L Benoist, M E Cornet, D R Hoven, A B Rinia, W J Fokkens, S Reitsma

{"title":"嗜酸性粒细胞是目前对严重的、无法控制的、伴有鼻息肉的慢性鼻窦炎进行生物治疗的主要 2 型标志物。","authors":"R van der Lans, J J Otten, G F J P M Adriaensen, L B L Benoist, M E Cornet, D R Hoven, A B Rinia, W J Fokkens, S Reitsma","doi":"10.4193/Rhin23.081","DOIUrl":null,"url":null,"abstract":"The latest European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS2020) defines markers for type2 inflammation in the context of indicating biological therapy in severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) as either a total serum immunoglobulin E (total-IgE) <100 kU/L, a blood eosinophil count (BEC, expressed as -109 cells / L) >=0.25, or a tissue eosinophil count >=10 per high power field (HPF) (1). Recently, an EPOS/EUFOREA expert panel advised to lower the threshold for BEC from >=0.25 (EPOS2020) to >=0.15 (EUFOREA2023) to align with thresholds used for biological indication in asthma patients (2). As far as we know, there is no literature supporting the cut-off value for total-IgE.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":"383-384"},"PeriodicalIF":4.8000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Eosinophils are the dominant type2 marker for the current indication of biological treatment in severe uncontrolled chronic rhinosinusitis with nasal polyps.\",\"authors\":\"R van der Lans, J J Otten, G F J P M Adriaensen, L B L Benoist, M E Cornet, D R Hoven, A B Rinia, W J Fokkens, S Reitsma\",\"doi\":\"10.4193/Rhin23.081\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The latest European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS2020) defines markers for type2 inflammation in the context of indicating biological therapy in severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) as either a total serum immunoglobulin E (total-IgE) <100 kU/L, a blood eosinophil count (BEC, expressed as -109 cells / L) >=0.25, or a tissue eosinophil count >=10 per high power field (HPF) (1). Recently, an EPOS/EUFOREA expert panel advised to lower the threshold for BEC from >=0.25 (EPOS2020) to >=0.15 (EUFOREA2023) to align with thresholds used for biological indication in asthma patients (2). As far as we know, there is no literature supporting the cut-off value for total-IgE.\",\"PeriodicalId\":21361,\"journal\":{\"name\":\"Rhinology\",\"volume\":\" \",\"pages\":\"383-384\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rhinology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4193/Rhin23.081\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rhinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4193/Rhin23.081","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

最新的《欧洲鼻炎和鼻息肉立场文件》（EPOS2020）规定，在对严重未控制的慢性鼻炎伴鼻息肉（CRSwNP）进行生物治疗时，2 型炎症的标志物为血清总免疫球蛋白 E（total-IgE）>100 kU/L、血液嗜酸性粒细胞计数（BEC，以 -109 cells / L 表示）≥0.25 或每高倍视野（HPF）组织嗜酸性粒细胞计数≥10（1）。25，或组织嗜酸性粒细胞计数≥10个/高倍视野（HPF）（1）。最近，EPOS/EUFOREA 专家小组建议将 BEC 的阈值从≥0.25（EPOS2020）降低到≥0.15（EUFOREA2023），以便与哮喘患者生物适应症的阈值保持一致（2）。据我们所知，没有文献支持总 IgE 的临界值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Eosinophils are the dominant type2 marker for the current indication of biological treatment in severe uncontrolled chronic rhinosinusitis with nasal polyps.

The latest European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS2020) defines markers for type2 inflammation in the context of indicating biological therapy in severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) as either a total serum immunoglobulin E (total-IgE) <100 kU/L, a blood eosinophil count (BEC, expressed as -109 cells / L) >=0.25, or a tissue eosinophil count >=10 per high power field (HPF) (1). Recently, an EPOS/EUFOREA expert panel advised to lower the threshold for BEC from >=0.25 (EPOS2020) to >=0.15 (EUFOREA2023) to align with thresholds used for biological indication in asthma patients (2). As far as we know, there is no literature supporting the cut-off value for total-IgE.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Rhinology 医学-耳鼻喉科学

CiteScore

15.80

自引率

9.70%

发文量

135

审稿时长

6-12 weeks

期刊介绍： Rhinology serves as the official Journal of the International Rhinologic Society and is recognized as one of the journals of the European Rhinologic Society. It offers a prominent platform for disseminating rhinologic research, reviews, position papers, task force reports, and guidelines to an international scientific audience. The journal also boasts the prestigious European Position Paper in Rhinosinusitis (EPOS), a highly influential publication first released in 2005 and subsequently updated in 2007, 2012, and most recently in 2020. Employing a double-blind peer review system, Rhinology welcomes original articles, review articles, and letters to the editor.